Premium
Paradoxical effect of SARS‐CoV‐2 infection in patients with immune thrombocytopenia
Author(s) -
CruzBenito Beatriz,
RivasPollmar María I.,
Álvarez Román María T.,
TrellesMartínez Roberto,
MartínSalces Monica,
Lázarodel Campo Paula,
RamírezLópez Andrés,
GarcíaBarcenilla Sara,
Cebanu Tamara,
AcuñaButta Paula,
MonzónManzano Elena,
GonzálezZorrilla Elena,
JiménezYuste Victor,
Butta Nora V.
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17077
Subject(s) - medicine , discontinuation , immune thrombocytopenia , thrombocytosis , immunology , complication , immune system , population , retrospective cohort study , coronavirus , covid-19 , disease , platelet , infectious disease (medical specialty) , environmental health
Summary Thrombocytopenia has been identified as a common complication of severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in the general population. In an attempt to determine the impact of coronavirus disease 2019 (COVID‐19) in patients with immune thrombocytopenia (ITP), a retrospective single‐centre study was performed. Thrombocytosis was observed in patients with chronic ITP after SARS‐CoV‐2 infection, frequently needing treatment adjustment or even discontinuation of therapy. Relapses and newly diagnosed cases showed a fast response after initial treatment compared to ITP. Reduced immune activity due to lymphopenia during COVID‐19 could explain this paradoxical effect, although further studies are needed.